Tuberculosis remains a major health problem affecting millions of people worldwide (5) . Combination chemotherapy is very effective in curing this disease but, unfortunately, the treatment is long and expensive and requires stringent compliancy to avoid the development of multi-drug-resistant forms of Mycobacterium tuberculosis. The only tuberculosis vaccine currently available is an attenuated strain of M. bovis, termed bacillus Calmette-Guérin (BCG). BCG continues to be widely administered to children in developing countries, yet its efficacy remains controversial, particularly against pulmonary tuberculosis in young adults (4) . Clearly, the development of a better vaccine could be an effective solution to the global threat of tuberculosis.
The protective antigens for tuberculosis are still not precisely defined, and this seriously hampers every effort to improve or replace the existing tuberculosis vaccine. It has been hypothesized for more than a decade that extracellular (secreted or cell-wall-associated) proteins rather than intracellular, cytoplasmic proteins are the key antigens recognized by the protective immune response (27) . Immunization with whole culture filtrate, which is a rich source of these exported proteins, has been described to protect mice and guinea pigs to some extent against subsequent challenge with the tubercle bacillus (1, 17, 28, 29) . A major portion of the secreted proteins in M. tuberculosis and BCG culture filtrate is formed by the Ag85 complex, a 30-to 32-kDa family of proteins (Ag85A, Ag85B, and Ag85C) (39) . Ag85 complex induces strong T-cell proliferation and gamma interferon (IFN-␥) production in most healthy individuals infected with M. tuberculosis or M. leprae and in BCG-vaccinated mice and humans (19, 24, 30, 31) , making it a promising candidate as a protective antigen. We have previously shown that intramuscular (i.m.) vaccination with plasmid DNA encoding Ag85A induced strong humoral and cell-mediated immune responses and conferred significant protection in C57BL/6 mice challenged by aerosol with live M. tuberculosis H37Rv (20) .
Administration of plasmid DNA expression vectors seems broadly applicable for generating protective immune responses against infectious pathogens without the need for live organisms, replicating vectors, or adjuvants (12, 35) . Two major inoculation routes have been used so far for DNA vaccination: i.m. needle injection of DNA in saline (40) and epidermal gene gun (gg) bombardment with DNA-coated gold particles (32) . For i.m. injections, routine doses of DNA in the mouse range between 10 and 100 g. gg injections use considerably less DNA, with standard doses of between 0.1 and 1 g. Because of the low plasmid doses used in gg immunizations, this technique has the potential of lower vaccine cost. Furthermore, mixing of a number of plasmids is possible in gg vaccination, and pools of plasmids can be screened by expression library immunization (3). Finally, gg immunization does not require the use of needles, which makes it an ideal method for use in children and human immunodeficiency virus-infected populations; also, this technique is easier to apply to a large-scale immunization.
In order to analyze whether gg immunization with plasmid DNA would be applicable to tuberculosis, we have compared the two current DNA immunization protocols, i.e., i.m. needle injection and gg bombardment with plasmid DNA encoding Ag85A from M. tuberculosis. Since we have previously shown that C57BL/6 mice demonstrate a stronger Th1-type immune response toward Ag85 following M. bovis BCG vaccination than BALB/c mice (in which this response in partly counterbalanced by Th2 cells) (19) , comparative analysis of the gg and i.m. routes was performed on both strains. Whereas gg immunization induced strong antibody and CTL responses, Th1-type cytokine production was disappointingly low compared to i.m. immunization. Furthermore and unexpectedly, gg immunization was effective only in BALB/c mice and not in C57BL mice.
MATERIALS AND METHODS
Plasmid construction. Plasmid DNA encoding Ag85A was prepared as described previously. Briefly, the 85A gene of M. tuberculosis was amplified without its mycobacterial signal sequence from plasmid p85A.tub (7) by PCR and ligated to the dephosphorylated VR1020 (Vical, Inc., San Diego, Calif.) vector. Recombinant plasmid DNA was amplified in Escherichia coli DH5 and purified on two cesium chloride-ethidium bromide gradients. Plasmid DNA was adjusted to a final concentration of 1 mg/ml in saline and stored at Ϫ20°C. In this plasmid, the Ag85A gene is expressed under control of the promoter and intron A of the first immediate-early antigen IE1 from cytomegalovirus and followed by a polyadenylation site of the bovine growth hormone. In the VR1020 vector a leader sequence of human tissue plasminogen activator is cloned upstream of the mature Ag85A gene, resulting in increased transcription and translation efficacy and increased immunogenicity (2) .
Mice. Coating of gold beads. Gold beads were coated with plasmid DNA according to the manufacturer's recommendations. In short, 25 mg of gold powder was mixed with 100 l of spermidine (0.05 M; Sigma) and sonicated. Next, 500 g (first experiment) or 100 g (all other experiments) of plasmid DNA encoding Ag85A in a 100-l volume was added. Finally, 200 l of 1 M CaCl 2 was added dropwise to the mixture with gentle vortexing. After a 10-min precipitation step at room temperature, the pellets were washed three times and then resuspended in 100% ethanol. Finally, the pellets were resuspended in an ethanol solution containing 0.01 mg polyvinylpyrrolidone (Bio-Rad) per ml and coated on special tubing (Gold-Coat tubing; Bio-Rad). Cut cartridges containing nitrogen-dried DNA-coated gold beads were stored at Ϫ20°C. gg immunization. Mice were vaccinated on the shaved ventral skin using the Helios Gene Gun System (Bio-Rad) at a helium discharge pressure of 400 lb/in 2 . In the first experiment, three gg immunizations were performed at 3-week intervals, consisting of two nonoverlapping shots of 0.5 mg of either 0.6, 1, or 1.6-m-diameter gold beads coated with 5 g of plasmid DNA. In the other experiments, mice were vaccinated three times at 3-week intervals with two nonoverlapping shots of 1-m gold beads coated with 1 g of plasmid DNA.
i.m. DNA vaccination. Mice were anesthetized by an intraperitoneal injection of ketamine and xylazine (100 and 10 mg/kg, respectively) and injected i.m. in both quadriceps with plasmid DNA encoding Ag85A in saline, using a 0.3-ml insulin syringe (Becton Dickinson). Mice received three injections at 3-week intervals of 10 g of Ag85A encoding DNA in the first experiment and of 100 g of Ag85A DNA in the other experiments.
Antigens. Antigen 85A was purified from M. bovis BCG culture filtrate as described previously by sequential chromatography on phenyl-Sepharose, DEAE-Sephacel ion exchange, and molecular sieving on Sephadex G75 (10) . Pokeweed mitogen (PWM; Gibco-BRL) was used as a T-cell-dependent B-cell mitogen to analyze polyclonal cytokine secretion.
ELISA. Sera from gene gun and needle injected mice were collected by orbital bleeding 3 weeks after each DNA vaccination. Levels of anti-Ag85 antibodies were determined by enzyme-linked immunosorbent assay (ELISA) in sera from individual mice (three to five/group). The serum titer was converted to antibody concentration (in nanograms/milliliter) by comparison with a standard monoclonal antibody, and the mean antibody concentration was calculated from at least three points of the linear portion of the titration curve. Concentrations were converted to log 10 values. For isotype analysis, peroxidase-labeled, rat antimouse immunoglobulin G1 (IgG1), IgG2a, and IgG2b (Experimental Immunology Unit, Université Catholique de Louvain, Brussels, Belgium) were used. Titers were expressed in dilution endpoints (last serum dilution with an optical density [OD] value higher than a cutoff OD value calculated from the OD with the secondary antibody only plus three standard deviations (SD). [20] ).
Cytokine production. DNA-vaccinated mice were sacrificed 3 weeks after the third DNA vaccination, and spleens were removed aseptically. Spleens from three mice were analyzed individually in each group. Spleen cells were adjusted to a concentration of 4 ϫ 10 6 cells/ml and were grown in round-bottom microwell plates (Nunc), in RPMI 1640 (Gibco-BRL) medium supplemented with glutamine, HEPES, 50 mM 2-mercaptoethanol, antibiotics, and 10% heat-inactivated fetal calf serum (Gibco-BRL). A volume of 180 l of cell suspension was added to a 20-l volume of purified Ag85A (final concentration, 5 g/ml) or PWM (dilution of 1:50 of stock solution). Cells were incubated at 37°C in a humidified CO 2 incubator, and supernatants were harvested after 24 h (interleukin-2 [IL-2]) and 72 h (IL-4, IL-10, and IFN-␥). Supernatants from three separate wells were pooled and stored frozen at Ϫ20°C until assay.
IL-2 assay. IL-2 activity was measured using a bioassay, as reported before (19) . Each sample was tested in duplicate. IL-2 levels are expressed as the mean counts per minute (cpm). The SD was Ͻ10%. In this assay, 50,000 cpm correspond to 3.12 IU/ml (19) , or about 600 pg/ml, and the detection limit was ca. 10 pg/ml. IFN-␥ assay. Antiviral IFN-␥ activity was quantified in duplicate on 72-h culture supernatants by using a bioassay, as reported before (21) . Titers are expressed as mean log 2 values obtained in three to five individual mice. The value of log 2 ϭ 1 corresponds to 110 pg/ml as measured in the Genzyme Mouse Interferon-␥ DuoSet (80-3931-00). The detection limit of the bioassay was about 75 pg/ml. IL-4 assay. IL-4 activity was measured on a 72-h culture supernatant by ELISA using the Genzyme IL-4 DuoSet (80-3537-00).
IL-10 assay. IL-10 activity was measured on a 72-h culture supernatant by ELISA using the Genzyme Mouse IL-10 ELISA kit (80-3749-05).
In vitro stimulation of cytotoxic T lymphocytes (CTLs). Spleen cells (5 ϫ 10 6 /well) from DNA-vaccinated BALB/c mice were cultured for 6 days in 24-well plates with the immunodominant major histocompatibility complex type I (MHC-I) K d -restricted peptide (amino acids 144 to 152 (VYAGAMSGL) from Ag85A (11) .
Cytolytic assay. CTL assay was performed as described previously (11) . Briefly, lymphocytes from the stimulated cultures were tested for cytotoxicity in a 4-h 51 Cr release assay in round-bottom microwell plates with 10 4 51
Cr-labeled P815 cells pulsed with peptide VYAGAMSGL (5 g/ml) at various effector/ target ratios. Data are expressed as the percent specific lysis. Spontaneous release was generally 10 to 15% of the total release.
M. tuberculosis challenge. BALB/c and C57BL/6 mice were vaccinated three times at 3-week intervals with control plasmid or Ag85A DNA either by gg bombardment (two shots, 1 g/shot) or by i.m. injection (two injections, 50 g/injection). Mice were rested for 2 months after the third DNA immunization and challenged intravenously in a lateral tail vein with 10 6 CFU of M. tuberculosis H37Rv grown as a surface pellicle for 2 weeks on synthetic Sauton medium and stored as a stock solution at Ϫ70°C in glycerol. Four weeks after challenge, mice were sacrificed, and serial threefold spleen and lung homogenate dilutions were plated on 7H11 Middlebrook agar supplemented with OADC (33) . Petri dishes were incubated for 4 weeks in sealed plastic bags at 37°C, and colonies were counted visually. For statistical analysis (Student's t test), data obtained from two or three dilutions were used to calculate the mean log 10 CFU values per spleen or lung. Data are expressed as mean log 10 values per experimental group (each consisting of four to six animals).
RESULTS
Antibody production in mice vaccinated with 10 g of plasmid DNA encoding Ag85A from M. tuberculosis administered i.m. by needle or epidermally with gold particles of three different sizes. In a preliminary experiment, we compared gg and i.m. administration of a same dose of plasmid DNA, i.e., 10 g/injection. Although this dose was probably not optimal for either route (too high for gg method and too low for the i.m. method), the idea was to have the same level of immunostimulatory effects linked to the CpG ODN content (23) of the vector backbone for both immunization routes. Ag85A DNA was administered three times at 3-week intervals to BALB/c or C57BL/10 mice, either by i.m. injection in saline in both quadricep muscles (5 g/hind leg) or epidermally by two gg injections in the abdomen using DNA-coated gold particles 0.6, 1, and 1.6 m in diameter (5 g/bead). Mice were bled 3 weeks after the last DNA inoculation. As shown in Fig. 1 , significant Ag85-specific antibody production could be detected following gg vaccination in BALB/c mice, whereas antibody levels in gg-injected B10 mice were only slightly above values obtained in mice vaccinated by gg with empty VR1020 vector. A bead size of 1 m was found to give the best antibody response. i.m. vaccination with 10 g of plasmid DNA induced elevated antibody levels in B10 mice, but this dose was too low to be effective in BALB/c mice. Mean Ag85A-specific antibody levels in gg-injected BALB/c mice were ca. 40,000 ng/ml, and mean antibody levels in i.m. vaccinated B10 mice were ca. 75,000 ng/ml.
As shown in Fig. 2 , antibody levels in gg-vaccinated BALB/c mice started to increase after the second shot of DNA and increased further after the third gg administration. After i.m. immunization of B10 mice, immunoglobulin antibodies started to increase already after one injection, and concentrations increased after the second and third immunization. In gg-immunized B10 mice and in i.m.-immunized BALB/c mice, antibody levels were close to the control values found in mice vaccinated with empty vector.
Antibody production in mice vaccinated with plasmid DNA encoding Ag85A from M. tuberculosis administered i.m. (100 g/injection) or by gg (2 g/injection). Since plasmid doses used in the first experiment were probably not optimal, we decided to compare the two immunization routes at the more classical doses used, i.e., the low dose of 2 g by the gg route and the high dose of 100 g by the i.m. route. As shown in Table 1 , gg immunization again induced significant antibody production in BALB/c mice, whereas B10 mice (and B6 mice [data not shown]) again reacted only modestly to this immunization route. In contrast, i.m. injection with the high dose of DNA induced elevated antibody production in both mouse strains.
Antibody isotype in mice vaccinated by the gg or the i.m. route with plasmid DNA encoding Ag85A from M. tuberculosis. Antibody responses in gg-vaccinated BALB/c and B10 mice were preferentially of the IgG1 isotype with little IgG2a, a finding indicative of Th2-type helper-T-cell activation (37) . In contrast, antibody isotypes in i.m.-vaccinated C57BL/10 mice were strongly indicative of Th1 activation, with IgG2a and IgG2b titers 10-to 20-fold higher than IgG1 titers both at low and high DNA doses. Isotypes in i.m.-vaccinated BALB/c mice were of a mixed phenotype, even at the high DNA dose used, indicating that it is not only the dose of DNA that determines the isotype profile in DNA vaccination, but the genetic background of the mouse strain as well. Antibody isotypes in i.m.-vaccinated B6 mice were also strongly biased towards IgG2 (20) .
IL-2 and IFN-␥ production in mice vaccinated by the gg or the i.m. route with plasmid DNA encoding Ag85A from M. tuberculosis. As shown in Fig. 3A , spleen cells from BALB/c mice vaccinated with plasmid DNA encoding Ag85A produced weak IL-2 levels in response to purified Ag85A following gg or low-dose i.m. injection. High-dose i.m. DNA induced significant IL-2 production in BALB/c mice. In B10 mice, elevated IL-2 levels could be induced following i.m. vaccination with both low and high doses of DNA, whereas gg vaccination was completely ineffective for IL-2 induction in B10 mice. As for IL-2, IFN-␥ production in spleen cell cultures from DNAvaccinated mice restimulated in vitro with purified Ag85A was highest in B10 mice injected i.m. (about 6 log 2 U, corresponding to ca. 3,200 pg of IFN-␥ per ml (Fig. 3B) . Spleen cell cultures from BALB/c mice produced considerably lower titers (between 400 and 800 pg/ml) following either gg or low-dose i.m. injection, whereas significantly better IFN-␥ production, albeit still at least twofold lower than in B10 mice, was observed upon high-dose i.m. immunization. As for IL-2, gg vaccination elicited only a marginal Ag85-specific IFN-␥ response (ca. 100 pg/ml) in spleen cell cultures from B10 (or B6 [data not shown]) mice.
CTL responses in BALB/c mice vaccinated by the gg or the i.m. route with plasmid DNA encoding Ag85A from M. tuberculosis. So far we have only been able to detect Ag85A-specific CD8 ϩ -mediated CTL activity (as measured in a 51 Cr release assay) following i.m. immunization in BALB/c mice but not in B10 or B6 mice (11) . Whether this lack of detectable CTL activity in H-2 b mice vaccinated with Ag85A DNA is a technical problem or related to an absence of immunodominant (Fig. 4) . As for antibody responses, gg immunization was effective for the induction of CTL responses at plasmid doses 50-fold lower than those required for optimal CTL induction by i.m. immunization. i.m. immunization with doses of 2 or 10 g of plasmid DNA induced only suboptimal CTL responses (data not shown).
IL-4 and interleukin-10 production in mice vaccinated with plasmid DNA encoding Ag85A from M. tuberculosis, administered i.m. or by gg with 1-m gold particles. As shown in Table   2 and as already described following i.m. immunization (20) , IL-4 and IL-10 production in spleen cells from gg-vaccinated mice was very low following in vitro restimulation with the purified Ag85A. However, production of these two Th2-type cytokines following polyclonal PWM stimulation showed that the basal production level was about fivefold higher in BALB/c mice than in B10 mice and that i.m. but not gg immunization could reduce the PWM-induced stimulation of IL-4 more than 10-fold. However, PWM-induced IL-4 levels in i.m.-vaccinated BALB/c mice were still considerable (ca. 1,000 pg/ml). PWMinduced IL-10 levels did not seem to be affected by either immunization route and remained at least five times higher in BALB/c than in B10 mice. were also protected by i.m. Ag85A DNA vaccination (data not shown). BALB/c mice were more susceptible to a same intravenous inoculum (10 6 CFU) of M. tuberculosis than B6 mice, as reflected by higher CFU counts, in spleen and lungs, in control DNA vaccinated animals.
Protection against M. tuberculosis

DISCUSSION
Over the last 4 years, we and others have reported that vaccination of mice with plasmid DNA encoding the 65-kDa heat shock protein (34), the 38-kDa phosphate-binding PstS-1 homolog (41), the 40-kDa phosphate-binding PstS-3 homolog (33), and the 30-to 32-kDa trehalose-mycolyl-transferase antigens 85A (20) and 85B (22) from M. tuberculosis is a powerful means for inducing strong humoral and cell-mediated immune responses and protective immunity against tuberculosis challenge (18) . All of these observations used the i.m. immunization route and, to our knowledge, no data on the immunogenicity or protective efficacy of tuberculosis DNA vaccines administered by gg have been published thus far.
Using plasmid DNA encoding the nucleoprotein and hemagglutinin from influenza. Feltquate et al. have reported that i.m. injection of BALB/c mice with saline solutions of DNA induces preferentially a Th1-type T-helper response, whereas epidermal gg injection biases the immune response toward a strong Th2-type profile (13, 36) . In order to find out whether this dichotomy could also be observed with plasmid DNA encoding mycobacterial genes, which are all characterized by a high GC content (ca. 70%) and therefore probably a high inherent CpG linked Th1-type immunostimulatory activity (23), we vaccinated BALB/c and C57BL mice with various doses of plasmid DNA encoding Ag85A from M. tuberculosis by epidermal gg bombardment or i.m. needle injection. Confirming Feltquate's data, the gg immunization was a very effective technique for inducing strong antibody responses, with an isotypic profile suggestive of Th2 activation. Plasmid doses needed for an optimal antibody response were at least 50-fold lower with the gg immunization than with i.m. immunization. A new finding, however, was that only BALB/c mice produced strong antibody responses following gg immunization, whereas C57BL mice were only very weakly stimulated by this immunization route. This discrepancy between the two mouse strains could not be attributed directly to MHC-linked differences, since MHC congenic BALB.B10 mice also demonstrated strong antibody responses following gg immunization (data not shown). BALB/c mice have been reported to be Th2 "prone" in a number of experimental situations, such as experimental leishmaniasis (16, 25) , BCG vaccination (19) , and tuberculosis infection (8) . It is tempting to speculate that this Th2 "proneness" of the genetic BALB/c background is the major factor determining their strong antibody reactivity following gg immunizations. Furthermore, the capacity to produce the Th2-type cytokines IL-4 and IL-10 following polyclonal stimulation with PWM was clearly higher in BALB/c mice than in B10 mice. In line with these findings, Virelizier previously reported that BALB/c mice produce significantly lower IFN-␥ titers in response to PWM than did B10 mice (38) . Finally, antibody isotypes were of a clearcut Th1 type in B10 mice vaccinated i.m. with DNA, but in BALB/c mice even the high i.m. dose of 100 g of plasmid DNA induced a mixed isotype profile with elevated IgG1 and IgG2 titers, indicating that it is very difficult to overcome this Th2 proneness of BALB/c mice with the Ag85A DNA vaccine. An in vivo dominance of the Th2 over the Th1 response might explain why the Ag85A DNA vaccine only conferred protection against an intravenous M. tuberculosis challenge in C57BL mice and not in BALB/c mice, although i.m. immunization clearly induced a strong IL-2 and IFN-␥ response in both mouse strains (although the B10 response was consistently higher than the BALB/c response). Interestingly, only i.m. vaccination of B10 mice completely blocked the PWM-induced IL-4 response, whereas in i.m.-vaccinated BALB/c mice this PWM-induced IL-4 response was still quite elevated, albeit somewhat reduced compared to the response of naive or gg-immunized BALB/c mice. With the exception of the 65-kDa heat shock protein, the new experimental tuberculosis vaccines, whether protein or DNA based, have all been tested in C57BL mice (1, 17, 20, 22, 26, 33, 41) . Whether they are also effective in BALB/c mice remains an open question in the light of the results presented here.
A new and unexpected finding was that C57BL mice reacted only weakly to the gg immunization protocol, even at a plasmid dose of 10 g, at which i.m. immunization induced elevated immune responses comparable to those induced by 100 g given i.m. As DNA vaccines prime for immune response through the action of professional antigen-presenting cells (APC) (9), our findings could indicate that the Langerhans cells from the skin (the probable APC population involved in gg immunization) would be more effective in some mouse strains, such as BALB/c and BALB.B10, than in others, such as B10 and B6.
Protective immunity with the Ag85A DNA vaccine could only be induced in B6 (and B10) mice and not in BALB/c mice and only by i.m. and not by gg immunization, thus demonstrating that high Th1-type IFN-␥ responses rather than strong CTL or antibody responses are critical immune parameters. Indeed, CD8
ϩ cell-mediated CTL activity was very efficiently induced in gg-vaccinated BALB/c mice, but no protection against intravenous M. tuberculosis challenge could be observed. As CD8 ϩ -mediated CTL responses require endogenous processing of the antigen, this generation of strong CTL responses despite low Th1 cytokine titers was not completely surprising, and this finding also highlights the potential of DNA vaccines with respect to the generation of MHC-I-restricted CD8 ϩ cell responses. This was corroborated recently by Fensterle et al., who reported on effective DNA vaccination by gg against listeriosis, an intracellular pathogen for which protection primarily depends on type 1 CD8 ϩ T cells (14) . However, the relevance of CD8 ϩ T-cell responses for protection against tuberculosis remains a matter of debate. Studies in mice genetically deleted for ␤ 2 -microglobulin have indicated that CD8
ϩ T cells play a role in the control of tuberculosis infection, particularly at later time points (15) . Thus far we have been unable to demonstrate Ag85A-specific CD8 ϩ responses in ϩ/ϩ B6 mice vaccinated with Ag85A DNA (probably because the Ag85A protein lacks the necessary immunodominant K b -and D b -restricted epitopes), although this vaccination can reduce significantly the early replication of M. tuberculosis in the spleen and lungs (33) . Moreover, challenge experiments on ␤ 2 -microglobulin knockout mice vaccinated with plasmid DNA encoding Ag85A also indicate that CD8 ϩ responses are not required for early protection against tuberculosis (C. D. D'Souza et al., submitted for publication).
In conclusion, strong Ag85A-specific and polarized Th1-type immune responses and protection against M. tuberculosis challenge could only be detected in C57BL mice following i.m. and not gg immunization with plasmid DNA encoding Ag85A. To what extent these findings can be extrapolated to other mycobacterial genes remains to be examined, but preliminary results indicate that the immunization of C57BL mice with plasmid DNA encoding another protective antigen of tuberculosis, i.e., the 40-kDa PstS-3 protein, is also ineffective when administered by gg (A. Tanghe et al., unpublished data).
It is not known at present whether similar genetic variations will be found in the immunogenicity of tuberculosis DNA vaccines in the highly polymorphic human population. However, it is clear that at least for an Ag85A DNA-based DNA vaccine a robust IFN-␥ rather than a CTL response seems to be needed for protective efficacy. Therefore, strong induction of this macrophage-activating cytokine without Th2-type counterbalancing cytokines appears to be the key element, and the magnitude of the IFN-␥ response rather than the origin (CD4 ϩ or CD8 ϩ , as reported by Bonato et al. (6) in the H-2 d haplotype mice vaccinated with DNA encoding the hsp65 antigen) may offer the best correlate of protection to be targeted in a new tuberculosis vaccine.
